Goals of treatment:

- 1. Eradication of infection.
- 2. Amelioration of signs and symptoms.
- 3. Prevention of the development of neurologic sequelae, such as seizures, deafness, coma, and death.

It is important to:

- 1) Prevent the disease through timely introduction of vaccination and chemoprophylaxis.
- 2) Understand antibiotic selection and the issues surrounding antibiotic penetration into the central nervous system.
- Until a pathogen is identified, immediate empirical antibiotic coverage is needed.

- The first dose of antibiotics should NOT be withheld, even when lumbar puncture is delayed or neuro-imaging is being performed; because changes in the CSF after antibiotic administration usually take up to 12 to 24 hours to occur.
- Continued therapy should be based on the assessment of clinical improvement, culture, and susceptibility testing results.
- Once a pathogen is identified, antibiotic therapy should be tailored to the specific pathogen.

Etiologies and Empirical Therapy by Age Group

Age	Most Likely Organisms	Empirical Therapy
<1 month	Streptococcus agalactiae Gram-negative enterics (E. coli, Klebsiella spp, Enterobacter spp) L. Monocytogenes	Ampicillin + cefotaxime <u>or</u> Ampicillin + aminoglycoside
1-23 months	S. pneumoniae N. meningitidis H. influenzae S. agalactiae	Vancomycin + 3rd generation cephalosporin (cefotaxime or ceftriaxone) Vancomycin to cover penicillin-resistant S. pneumoniae
2-50 years	N. meningitidis S. pneumoniae	Vancomycin + 3rd generation cephalosporin (cefotaxime or ceftriaxone) Vancomycin to cover penicillin-resistant S. pneumoniae
>50 years	S. pneumoniae N. meningitidis Gram-negative enterics (E. coli, Klebsiella spp, Enterobacter spp) L. monocytogenes	Vancomycin + ampicillin + 3rd generation cephalosporin (cefotaxime or ceftriaxone) Vancomycin to cover penicillin-resistant S. pneumoniae

Penetration of Antimicrobial Agents into the CSF

Therapeutic Levels in CSF With/Without Inflammation: Acyclovir, Levofloxacin, Chloramphenicol, Linezolid, Ciprofloxacin, Metronidazole, Fluconazole, Moxifloxacin, Flucytosine, Pyrazinamide, Foscarnet, Rifampin, Fosfomycin, Sulfonamides, Ganciclovir, Trimethoprim, Isoniazid, Voriconazole

Therapeutic Levels in CSF With **Inflammation of Meninges:** Ampicillin ± sulbactam, Imipenem, Aztreonam, Meropenem, Cefepime, Nafcillin, Cefotaxime, Ofloxacin, Ceftazidime, Penicillin G, Ceftriaxone, Piperacillin/tazobactam, Cefuroxime, Pyrimethamine, Colistin, Quinupristin/dalfopristin, Daptomycin, Ticarcillin ± clavulanic acid, Ethambutol, Vancomycin

Gram-Positive Organisms:

Streptococcus pneumoniae: duration 10-14 days.

1. Penicillin susceptible:

- Antibiotics of First Choice: Penicillin G or Ampicillin.
- Alternatives: Cefotaxime, Ceftriaxone, Cefepime or Meropenem.

2. Penicillin resistant:

- Antibiotics of First Choice: Vancomycin + Cefotaxime or Ceftriaxone.
- Alternatives: Moxifloxacin.

3. Ceftriaxone resistant:

- Antibiotics of First Choice: Vancomycin + Cefotaxime or Ceftriaxone.
- Alternative: Moxifloxacin.

Staphylococcus aureus: duration 14-21 days.

1. Methicillin susceptible:

- Antibiotics of First Choice: Nafcillin or Oxacillin.
- Alternative: Vancomycin or Meropenem.

2. Methicillin resistant:

- Antibiotics of First Choice: Vancomycin.
- Alternative: TMP-SMX or Linezolid.

Group B Streptococcus: duration 14-21 days.

- Antibiotics of First Choice: Penicillin G or Ampicillin ± Gentamicin.
- Alternative: Ceftriaxone or Cefotaxime.

Staph. epidermidis: duration 14-21 days.

- Antibiotics of First Choice: Vancomycin.
- Alternative: Linezolid.

Listeria monocytogenes: duration ≥ 21 days

- Antibiotics of First Choice: Penicillin G or Ampicillin ± Gentamicin.
- Alternative: Trimethoprim-sulfamethoxazole, Meropenem.

Gram-Negative Organisms:

Neisseria meningitidis: duration 7-10 days.

1. Penicillin susceptible:

- Antibiotics of First Choice: Penicillin G or Ampicillin.
- Alternatives: Cefotaxime or Ceftriaxone.

2. Penicillin resistant:

- Antibiotics of First Choice: Cefotaxime or Ceftriaxone.
- Alternatives: Meropenem or Moxifloxacin.

Haemophilus influenzae: duration 7-10 days.

1. β-lactamase negative:

- Antibiotics of First Choice: Ampicillin.
- Alternatives: Cefotaxime, Ceftriaxone, Cefepime or Moxifloxacin.

2. β-lactamase positive:

- Antibiotics of First Choice: Cefotaxime or Ceftriaxone.
- Alternatives: Cefepime or Moxifloxacin.

Enterobacteriaceae (Including E. coli and Klebsiella spp.): duration 21 days.

- Antibiotics of First Choice: Cefotaxime or Ceftriaxone.
- Alternatives: Cefepime, Moxifloxacin, Meropenem or Aztreonam.

Pseudomonas aeruginosa: duration 21 days.

- Antibiotics of First Choice: Cefepime or Ceftazidime
 ± Tobramycin.
- Alternatives: Ciprofloxacin, Meropenem, Piperacillin
 - + Tobramycin, Colistin sulfomethate, Aztreonam.

- Supportive care (administration of fluids, electrolytes, antipyretics, and analgesics) is critically important.
- Venous thromboembolism prophylaxis and intracranial pressure (ICP) monitoring may be needed.
- Mannitol 25% or hypertonic 3% saline may be needed to maintain an ICP of less than 15 mm Hg.
- Appropriate antibiotic therapy (empirical or definitive) should be started as soon as possible.

Dexamethasone as an Adjunctive Treatment for Bacterial Meningitis

- Dexamethasone is a commonly used adjunctive therapy in the treatment of meningitis.
- Corticosteroids inhibit the production of TNF, PAF and IL-1, potent proinflammatory cytokines.
- They also reduce cerebral edema, high ICP, neuronal injury, and vasculitis.
- Some clinical studies have shown that treatment with corticosteroids reduces both mortality and neurological sequelae in adults with communityacquired bacterial meningitis.

Dexamethasone as an Adjunctive Treatment for Bacterial Meningitis

- Corticosteroid use in bacterial meningitis was associated with lower rates of severe hearing loss, and neurological sequelae, but did not reduce overall mortality (some other studies).
- Current recommendations are with the use of adjunctive dexamethasone in infants and children (6 weeks of age and older) with H. influenza meningitis.
- The recommended intravenous dose is 0.15 mg/kg every 6 hours for 2 to 4 days, initiated 10 to 20 minutes prior to or concomitant with, but not after, the first dose of antibiotics.

Dexamethasone as an Adjunctive Treatment for Bacterial Meningitis

- With adjunctive dexamethasone use, signs and symptoms of GI bleeding and hyperglycemia, should be monitored carefully.
- However, routine use of dexamethasone in meningitis is still controversial.

Etiology:

- 1. Those arising from spread of infection from oropharynx, middle ear, and paranasal sinuses are commonly caused by streptococci and oral anaerobes (Actinomyces spp., Bacteroides spp., Fusobacterium spp., Peptostreptococcus).
- 2. Staphylococci, aerobic and gram-negative bacilli are commonly involved in postoperative abscesses or those following head trauma.

- 3. P. aeruginosa and Nocardia spp. can cause brain abscesses but are more commonly seen in immunocompromised patients.
- Brain abscesses are commonly polymicrobial, thus, empiric antimicrobial therapy should include antibiotics with activity against gram-positive, gram-negative, and anaerobic organisms:
- a) Vancomycin + a third- or fourth-generation cephalosporin + metronidazole, depending on risk factors.

- b) A carbapenem (meropenem) could replace the cephalosporin and metronidazole.
- De-escalation of therapy should be performed once a causative organism is identified.
- De-escalation means changing an empiric broad-spectrum antibiotic regimen to a narrower antibiotic regimen by changing the antimicrobial agent or changing from combination therapy to monotherapy.

- Duration of therapy should be determined for each individual patient and should include consideration of the causative pathogen, size of abscess, use of surgical treatment, and response to therapy.
- It is prolonged, usually 4-8 weeks.
- United Kingdom guidelines recommend 4-6
 weeks if the abscess has been drained or
 excised and 6-8 weeks if the abscess is treated
 without drainage.

The following categories require a longer duration of therapy (6-8 weeks or longer):

- 1. Patients with an organized capsule with evidence of tissue necrosis.
- 2. Patients with a multiloculated abscess.
- 3. Patients with lesions in vital locations such as the brain stem or the motor strip (particularly if not surgically drained).
- 4. Immunocompromised patients.
- 5. Needle aspiration rather than open surgical excision.

- Anticonvulsant therapy is recommended for at least 1 year, because seizures are common complication of brain abscesses.
- The benefit of dexamethasone in the treatment of brain abscess is unclear and not routinely recommended, unless signs of cerebral edema are identified.

Cryptococcus neoformans

- Mainly affect persons with underlying impaired immunity.
- Acquired by inhalation of spores from the environment leading to CNS infection and less commonly pulmonary disease.
- Rapid sterilization of CNS through rapid fungicidal activity is the main approach of induction therapy (2 - 6 weeks), followed by consolidation therapy for 8 weeks.

Cryptococcus neoformans

- Amphotericin B was the drug of choice for the treatment of acute cryptococcal meningitis due to its rapid fungicidal activity, despite poor penetration into the CSF.
- Amphotericin B (1 mg/kg/day) combined with flucytosine (100 mg/kg/day) for 2 weeks was more effective than amphotericin alone for 4 weeks, or in combination with fluconazole (400 mg twice daily) for 2 weeks in HIV-positive patients.
- Voriconazole in combination with amphotericin B can be used.

Cryptococcus neoformans

- Flucytosine is poorly tolerated, causing bone marrow suppression and GI distress.
- Careful monitoring of hematologic parameters, therapeutic drug monitoring (TDM) and dose adjustment for patients with renal insufficiency are recommended to avoid flucytosine-associated toxicities.
- Lipid formulations of amphotericin B at higher doses (3-5 mg/kg/day) can be used for HIV-positive patients with or predisposed to renal dysfunction and are recommended for organ-transplant recipients.

Mycobacterium tuberculosis

- Initial regimen of four drugs for empirical treatment of *M. tuberculosis* is recommended.
- This regimen consists of isoniazid, rifampin, pyrazinamide, and ethambutol for the first 2 months, followed by isoniazid plus rifampin for the remaining duration of therapy.
- Duration of treatment 9 12 months or longer with multiple-drug therapy.
- With rifampin-resistant strains duration may be 18 - 24 months.

Mycobacterium tuberculosis

- The recommended therapy for HIV-positive individuals is the same as for immunocompetent patients.
- Duration of treatment ≥ 24 months.
- Rifabutin may replace other rifamycins (rifampin) to minimize drug interactions with protease inhibitors and nonnucleoside reversetranscriptase inhibitors.

- The spread of some types of bacterial meningitis can be prevented by administering prophylactic antimicrobials to contacts of patients with bacterial meningitis.
- This prevents transmission of the bacteria to susceptible hosts, and eradicates the organism from the nasopharynx of those who are already colonized.
- Such therapy is recommended for close contacts of patients infected with:
 - H. influenzae or N. meningitidis.

- Close contacts are defined as house-hold or daycare members who sleep or eat in the same dwelling as the index patient.
- Therefore, health care workers do not require chemoprophylaxis unless close contact with the patient's secretions occurs, as in mouth-tomouth resuscitation.

Chemoprophylaxis for Neisseria meningitidis

Children < 5years	Ciprofloxacin single dose 30mg/kg po (max 125mg)
Children 5-12 years	Ciprofloxacin 250mg po single dose
Pregnant women	Ceftriaxone 250mg IM stat
Female adults on the oral contraceptive pill	Ciprofloxacin 500mg po single dose
Adults and children >12 years	Ciprofloxacin 500mg po single dose

Rifampin can be used, but the duration of therapy is 2 days.

Chemoprophylaxis for Haemophilus influenzae

Infants under 1 year of age	Rifampicin 10mg/kg once daily for 4 days
Adults and children	Rifampicin 20mg/kg once daily for 4 days up to max of 600mg/day
Pregnant women	Not indicated

Vaccination

 With Haemophilus influenzae type b, pneumococcal meningitis or Neisseria meningitidis Groups C, A, Y and W135, vaccination of contacts and index may be indicated.